CT-009 Prognostic Role of Lymphocyte to Monocyte Ratio in PTS Treated With CAR-T for Aggressive Lymphoma

Radhika Bansal, Henan Zhang, Kodi E. Martinez, Matthew Hathcock, Zuoyi Shao, Gabrielle Gonzalez McCoy, Anatilde Gonzalez-Guerrico, Nora Bennani, Jonas Paludo, Yucai Wang, Patrick B. Johnston, Stephen M. Ansell, Saad Kenderian, Luis Porrata, Jose C. Villasboas, Yi Lin

Research output: Contribution to journalArticlepeer-review


Background: Low absolute lymphocyte to monocyte ratio (ALC/AMC) predicts decreased survival in aggressive lymphoma (NHL) patients (pts) receiving chemotherapy and ASCT. We report the clinical significance of ALC/AMC and associated cellular phenotype changes in pts receiving chimeric antigen receptor T-cell (CART) therapy. Methods: We conducted a retrospective chart review of all pts who received axicabtagene ciloleucel for NHL at Mayo Clinic, Rochester between 6/2016 and 12/2020. ALC and AMC were obtained from the clinical lab before lymphodepletion chemotherapy (LD). The receiver operator curve was generated using nominal logistic regression on ALC/AMC to predict complete remission (CR). Survivals were calculated using the Kaplan- Meier method. Blood immune phenotypes were assayed by multiparametric flow. Results: Low ALC/AMC (≤0.8, n=29) prior to LD was associated with a lower CR rate (AUC=0.68, p=0.0004). Baseline characteristics were similar between the low and high ALC/AMC group (>0.8, n=52), except for the use of prior ASCT and bridging therapy. The low ALC/AMC group also had higher CRP on the day of CAR-T infusion and was associated with shorter EFS and OS (EFS: 2.6 vs. 6.4 months, P<0.0001; OS: 5.3 months vs. not reached, P=0.0006), respectively. The prognostic association remained statistically significant on multivariate analysis that included prior ASCT, bridging therapy, and CRP. Compared to the high ALC/AMC group, the low ALC/AMC group had decreased CD4 Tem and increased CD16+CCR2+ monocytes (n=26). In addition, when comparing patients who achieved CR initially and relapsed versus those who maintained durable CR for 6 months or longer, there was a difference in these phenotypes as well as the number of CD27+CD45RA+CD62L+ CD8 T cells and PD-1+TIGIT+ T cells. Conclusions: ALC/AMC is a clinically accessible test that is strongly associated with CAR-T response and survival. Immune characterization revealed that the biological effect is not just associated with cell numbers. Phenotypes such as monocytes with inflammatory capacity and T cell subsets may further distinguish between primary refractory disease, early relapse, and durable response. These data could inform future therapeutic strategies to improve clinical outcomes with CAR-T.

Original languageEnglish (US)
Pages (from-to)S430
JournalClinical Lymphoma, Myeloma and Leukemia
StatePublished - Oct 2022


  • CAR-T
  • CT
  • Lymphoma
  • biomarker

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'CT-009 Prognostic Role of Lymphocyte to Monocyte Ratio in PTS Treated With CAR-T for Aggressive Lymphoma'. Together they form a unique fingerprint.

Cite this